Literature DB >> 22371899

rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Patrick Beckert1, Doris Hillemann, Thomas A Kohl, Jörn Kalinowski, Elvira Richter, Stefan Niemann, Silke Feuerriegel.   

Abstract

The ribosomal L3 protein was identified as a novel target in linezolid (LZD)-resistant Mycobacterium tuberculosis strains. Next-generation sequencing confirmed rplC T460C as the sole mutation in an LZD-resistant M. tuberculosis H37Rv strain selected in vitro. Sequencing analysis revealed the rplC T460C mutation in eight further LZD-resistant isolates (three in vitro-selected mutants and five patient isolates, including isolates from three different patients that developed LZD resistance during treatment) but in none of the susceptible control strains (n = 84).

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22371899      PMCID： PMC3346602          DOI： 10.1128/AAC.06227-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Strategies against multidrug-resistant tuberculosis.

Authors:  R Loddenkemper; D Sagebiel; A Brendel
Journal:  Eur Respir J Suppl       Date:  2002-07

2.  Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus.

Authors:  Nicole Wolter; Anthony M Smith; David J Farrell; William Schaffner; Matthew Moore; Cynthia G Whitney; James H Jorgensen; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  Elvira Richter; Sabine Rüsch-Gerdes; Doris Hillemann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

4.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Authors:  G B Migliori; B Eker; M D Richardson; G Sotgiu; J-P Zellweger; A Skrahina; J Ortmann; E Girardi; H Hoffmann; G Besozzi; N Bevilacqua; D Kirsten; R Centis; C Lange
Journal:  Eur Respir J       Date:  2009-03-12       Impact factor: 16.671

5.  Linezolid in the treatment of multidrug-resistant tuberculosis.

Authors:  G F Schecter; C Scott; L True; A Raftery; J Flood; S Mase
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

6.  The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

Authors:  Karen L Leach; Steven M Swaney; Jerry R Colca; William G McDonald; James R Blinn; Lisa M Thomasco; Robert C Gadwood; Dean Shinabarger; Liqun Xiong; Alexander S Mankin
Journal:  Mol Cell       Date:  2007-05-11       Impact factor: 17.970

Review 7.  Extensively drug-resistant tuberculosis: current challenges and threats.

Authors:  Amita Jain; Rajesh Mondal
Journal:  FEMS Immunol Med Microbiol       Date:  2008-05-08

Review 8.  Oxazolidinones: activity, mode of action, and mechanism of resistance.

Authors:  Bülent Bozdogan; Peter C Appelbaum
Journal:  Int J Antimicrob Agents       Date:  2004-02       Impact factor: 5.283

9.  Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

10.  Current and novel antibiotics against resistant Gram-positive bacteria.

Authors:  Federico Perez; Robert A Salata; Robert A Bonomo
Journal:  Infect Drug Resist       Date:  2008-09-09       Impact factor: 4.003
View more
  26 in total

1.  Combined Effect of the Cfr Methyltransferase and Ribosomal Protein L3 Mutations on Resistance to Ribosome-Targeting Antibiotics.

Authors:  Kevin K Pakula; Lykke H Hansen; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Mutations in the bacterial ribosomal protein l3 and their association with antibiotic resistance.

Authors:  Rasmus N Klitgaard; Eleni Ntokou; Katrine Nørgaard; Daniel Biltoft; Lykke H Hansen; Nicolai M Trædholm; Jacob Kongsted; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

4.  Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.

Authors:  Zhaojing Zong; Wei Jing; Jin Shi; Shu'an Wen; Tingting Zhang; Fengmin Huo; Yuanyuan Shang; Qian Liang; Hairong Huang; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 5.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

6.  Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

Authors:  Gaëlle Guiewi Makafe; Yuanyuan Cao; Yaoju Tan; Mugweru Julius; Zhiyong Liu; Changwei Wang; Moses M Njire; Xingshan Cai; Tianzhou Liu; Bangxing Wang; Wei Pang; Shouyong Tan; Buchang Zhang; Wing Wai Yew; Gyanu Lamichhane; Jintao Guo; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

8.  Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.

Authors:  Shuo Zhang; Jiazhen Chen; Peng Cui; Wanliang Shi; Xiaohong Shi; Hongxia Niu; Denise Chan; Wing Wai Yew; Wenhong Zhang; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.

Authors:  Ming Zhang; Claudia Sala; Neeraj Dhar; Anthony Vocat; Vasan K Sambandamurthy; Sreevalli Sharma; Gwendolyn Marriner; V Balasubramanian; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

10.  Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.

Authors:  V Balasubramanian; S Solapure; H Iyer; A Ghosh; S Sharma; P Kaur; R Deepthi; V Subbulakshmi; V Ramya; V Ramachandran; M Balganesh; L Wright; D Melnick; S L Butler; V K Sambandamurthy
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.